Krystal's Vyjuvek becomes first topical gene therapy with FDA nod to treat rare skin disease

The first FDA-approved treatment for a rare, devastating skin disease has arrived in Krystal Biotech’s Vyjuvek.

The disease, called dystrophic epidermolysis bullosa (DEB) is hallmarked by extremely fragile skin that rips and blisters with even the slightest friction, leading to open wounds that are prone to skin infections and fibrosis. DEB sufferers are also at an increased risk of aggressive skin cancer.